Works matching DE "RALTEGRAVIR"
Results: 563
Suspected pharmacokinetic interaction between raltegravir and the 3D regimen of ombitasvir, dasabuvir and paritaprevir/ritonavir in an HIV-HCV liver transplant recipient.
- Published in:
- 2016
- By:
- Publication type:
- Letter
Pharmacokinetic and safety of raltegravir in pregnancy.
- Published in:
- 2012
- By:
- Publication type:
- Letter
Incidence of cancer and overall risk of mortality in individuals treated with raltegravir‐based and non‐raltegravir‐based combination antiretroviral therapy regimens.
- Published in:
- HIV Medicine, 2018, v. 19, n. 2, p. 102, doi. 10.1111/hiv.12557
- By:
- Publication type:
- Article
Plasma trough concentrations of darunavir/ritonavir and raltegravir in older patients with HIV-1 infection.
- Published in:
- HIV Medicine, 2017, v. 18, n. 7, p. 474, doi. 10.1111/hiv.12478
- By:
- Publication type:
- Article
Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients.
- Published in:
- HIV Medicine, 2017, v. 18, n. 1, p. 56, doi. 10.1111/hiv.12468
- By:
- Publication type:
- Article
Switch to raltegravir decreases soluble CD14 in virologically suppressed overweight women: the Women, Integrase and Fat Accumulation Trial.
- Published in:
- HIV Medicine, 2014, v. 15, n. 7, p. 431, doi. 10.1111/hiv.12128
- By:
- Publication type:
- Article
Switch from tenofovir to raltegravir increases low bone mineral density and decreases markers of bone turnover over 48 weeks.
- Published in:
- HIV Medicine, 2014, v. 15, n. 6, p. 373, doi. 10.1111/hiv.12123
- By:
- Publication type:
- Article
Raltegravir-emtricitabine-tenofovir as HIV nonoccupational post-exposure prophylaxis in men who have sex with men: safety, tolerability and adherence.
- Published in:
- HIV Medicine, 2014, v. 15, n. 1, p. 13, doi. 10.1111/hiv.12075
- By:
- Publication type:
- Article
Pharmacokinetics of the combination raltegravir/atazanavir in HIV-1-infected patients Pharmacokinetics of the combination raltegravir/atazanavir in HIV-1-infected patients.
- Published in:
- HIV Medicine, 2013, v. 14, n. 7, p. 449, doi. 10.1111/hiv.12029
- By:
- Publication type:
- Article
Longitudinal analysis of integrase N155 H variants in heavily treated patients failing raltegravir-based regimens.
- Published in:
- HIV Medicine, 2013, v. 14, n. 2, p. 85, doi. 10.1111/j.1468-1293.2012.01039.x
- By:
- Publication type:
- Article
Safety and efficacy of raltegravir in patients with HIV-1 and hepatitis B and/or C virus coinfection.
- Published in:
- HIV Medicine, 2012, v. 13, n. 2, p. 127, doi. 10.1111/j.1468-1293.2011.00933.x
- By:
- Publication type:
- Article
UV -- SPECTROPHOTOMETRIC METHOD FOR ESTIMATION OF RALTEGRAVIR IN BULK AND TABLET DOSAGE FORM.
- Published in:
- International Journal of Pharmaceutical, Chemical & Biological Sciences, 2014, v. 4, n. 4, p. 807
- By:
- Publication type:
- Article
Raltegravir in HIV-1 Infection: Safety and Efficacy in Treatment-Naïve Patients.
- Published in:
- Clinical Medicine Reviews in Therapeutics, 2012, v. 4, p. 13, doi. 10.4137/CMRT.S5022
- By:
- Publication type:
- Article
Phenotypic analysis of HIV-1 E157Q integrase polymorphism and impact on virological outcome in patients initiating an integrase inhibitor-based regimen.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Decreased darunavir concentrations during once-daily co-administration with maraviroc and raltegravir: OPTIPRIM-ANRS 147 trial.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Implications of integrase inhibitors for HIV-infected transplantation recipients: Raltegravir and dolutegravir (S/GSK 1349572).
- Published in:
- BioScience Trends, 2011, v. 5, n. 5, p. 189, doi. 10.5582/bst.2011.v5.5.189
- By:
- Publication type:
- Article
HIV drug may have additional application as herpes virus replication inhibitor.
- Published in:
- Expert Review of Clinical Pharmacology, 2010, v. 3, n. 6, p. 719
- Publication type:
- Article
Assessment of risk factors for virological nonsuppression following switch to dolutegravir and lamivudine, or bictegravir, emtricitabine, and tenofovir alafenamide fumarate in a real-world cohort of treatment-experienced adults living with HIV.
- Published in:
- PLoS ONE, 2024, v. 19, n. 11, p. 1, doi. 10.1371/journal.pone.0314003
- By:
- Publication type:
- Article
Viral load suppression and HIV-1 drug resistance mutations in persons with HIV on TLD/TAFED in Zambia.
- Published in:
- PLoS ONE, 2024, v. 19, n. 9, p. 1, doi. 10.1371/journal.pone.0308869
- By:
- Publication type:
- Article
Determinants of virological failure among HIV clients on second-line antiretroviral treatment at Felege-hiwot and University of Gondar comprehensive specialized hospitals in the Amhara Region, Northwest Ethiopia: A case-control study.
- Published in:
- PLoS ONE, 2024, v. 19, n. 7, p. 1, doi. 10.1371/journal.pone.0289450
- By:
- Publication type:
- Article
Observational study of effects of HIV acquisition and antiretroviral treatment on biomarkers of systemic immune activation.
- Published in:
- PLoS ONE, 2024, v. 19, n. 7, p. 1, doi. 10.1371/journal.pone.0288895
- By:
- Publication type:
- Article
Incidence of lost to follow up among HIV-positive children on antiretroviral therapy in Ethiopia: Systematic review and meta-analysis.
- Published in:
- PLoS ONE, 2024, v. 19, n. 5, p. 1, doi. 10.1371/journal.pone.0304239
- By:
- Publication type:
- Article
Prevalence, treatment, and factors associated with cryptococcal meningitis post introduction of integrase inhibitors antiretroviral based regimens among People Living with HIV in Tanzania.
- Published in:
- PLoS ONE, 2024, v. 19, n. 2, p. 1, doi. 10.1371/journal.pone.0294940
- By:
- Publication type:
- Article
Effectiveness, durability and safety of dolutegravir and lamivudine versus bictegravir, emtricitabine and tenofovir alafenamide in a real-world cohort of HIV-infected adults.
- Published in:
- PLoS ONE, 2023, v. 18, n. 9, p. 1, doi. 10.1371/journal.pone.0291480
- By:
- Publication type:
- Article
Plasma Concentrations of Rosmarinic Acid in Patients on Antiretroviral Therapy: In Silico Exploration Based on Clinical Data.
- Published in:
- International Journal of Molecular Sciences, 2024, v. 25, n. 4, p. 2230, doi. 10.3390/ijms25042230
- By:
- Publication type:
- Article
The Integrase: An Overview of a Key Player Enzyme in the Antiviral Scenario.
- Published in:
- International Journal of Molecular Sciences, 2023, v. 24, n. 15, p. 12187, doi. 10.3390/ijms241512187
- By:
- Publication type:
- Article
Antiretroviral Treatment of HIV-2 Infection: Available Drugs, Resistance Pathways, and Promising New Compounds.
- Published in:
- 2023
- By:
- Publication type:
- Literature Review
High Instantaneous Inhibitory Potential of Bictegravir and the New Spiro-β-Lactam BSS-730A for HIV-2 Isolates from RAL-Naïve and RAL-Failing Patients.
- Published in:
- International Journal of Molecular Sciences, 2022, v. 23, n. 22, p. 14300, doi. 10.3390/ijms232214300
- By:
- Publication type:
- Article
Genetic Analysis of HIV-1 Integrase Sequences from Treatment Naive Individuals in Northeastern South Africa.
- Published in:
- International Journal of Molecular Sciences, 2013, v. 14, n. 3, p. 5013, doi. 10.3390/ijms14035013
- By:
- Publication type:
- Article
Incidence and risk factors for liver enzymes elevations in highly treatment-experienced patients switching from enfuvirtide to raltegravir: a sub-study of the ANRS-138 EASIER trial.
- Published in:
- AIDS Research & Therapy, 2016, p. 1, doi. 10.1186/S12981-016-0101-3
- By:
- Publication type:
- Article
Treatment with integrase inhibitor suggests a new interpretation of HIV RNA decay curves that reveals a subset of cells with slow integration.
- Published in:
- PLoS Pathogens, 2017, v. 13, n. 7, p. 1, doi. 10.1371/journal.ppat.1006478
- By:
- Publication type:
- Article
Explaining the Determinants of First Phase HIV Decay Dynamics through the Effects of Stage-dependent Drug Action.
- Published in:
- PLoS Computational Biology, 2013, v. 9, n. 3, p. 1, doi. 10.1371/journal.pcbi.1002971
- By:
- Publication type:
- Article
Emergent resistance-associated mutations at first- or second-line HIV-1 virologic failure with second-generation InSTIs in two- and three-drug regimens: the Virostar-1 study.
- Published in:
- Journal of Antimicrobial Chemotherapy (JAC), 2025, v. 80, n. 1, p. 95, doi. 10.1093/jac/dkae377
- By:
- Publication type:
- Article
DORAVIR: a French national survey of people with HIV-1 treated with an antiretroviral regimen including doravirine.
- Published in:
- Journal of Antimicrobial Chemotherapy (JAC), 2024, v. 79, n. 8, p. 1974, doi. 10.1093/jac/dkae194
- By:
- Publication type:
- Article
Fostemsavir to overcome drug–drug interactions in heavily treatment-experienced people with HIV and cancer.
- Published in:
- Journal of Antimicrobial Chemotherapy (JAC), 2024, v. 79, n. 7, p. 1708, doi. 10.1093/jac/dkae121
- By:
- Publication type:
- Article
Correction to: Trends of pre-treatment drug resistance in antiretroviral-naïve people with HIV-1 in the era of second-generation integrase strand-transfer inhibitors in Taiwan.
- Published in:
- Journal of Antimicrobial Chemotherapy (JAC), 2024, v. 79, n. 6, p. 1471, doi. 10.1093/jac/dkae131
- Publication type:
- Article
Trends of pre-treatment drug resistance in antiretroviral-naïve people with HIV-1 in the era of second-generation integrase strand-transfer inhibitors in Taiwan.
- Published in:
- Journal of Antimicrobial Chemotherapy (JAC), 2024, v. 79, n. 5, p. 1157, doi. 10.1093/jac/dkae086
- By:
- Publication type:
- Article
Drug resistance and influencing factors in HIV-1-infected individuals under antiretroviral therapy in Guangxi, China.
- Published in:
- Journal of Antimicrobial Chemotherapy (JAC), 2024, v. 79, n. 5, p. 1142, doi. 10.1093/jac/dkae084
- By:
- Publication type:
- Article
Temporal trends and transmission dynamics of pre-treatment HIV-1 drug resistance within and between risk groups in Kenya, 1986–2020.
- Published in:
- Journal of Antimicrobial Chemotherapy (JAC), 2024, v. 79, n. 2, p. 287, doi. 10.1093/jac/dkad375
- By:
- Publication type:
- Article
Efficacy and safety of raltegravir plus lamivudine maintenance therapy.
- Published in:
- Journal of Antimicrobial Chemotherapy (JAC), 2024, v. 79, n. 2, p. 255, doi. 10.1093/jac/dkad364
- By:
- Publication type:
- Article
Impact of pretreatment low-abundance HIV-1 drug resistance on virological failure after 1 year of antiretroviral therapy in China.
- Published in:
- Journal of Antimicrobial Chemotherapy (JAC), 2023, v. 78, n. 11, p. 2743, doi. 10.1093/jac/dkad297
- By:
- Publication type:
- Article
Comment on: Doravirine plus lamivudine two-drug regimen as maintenance antiretroviral therapy in people living with HIV: a French observational study.
- Published in:
- Journal of Antimicrobial Chemotherapy (JAC), 2023, v. 78, n. 11, p. 2780, doi. 10.1093/jac/dkad294
- By:
- Publication type:
- Article
Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens.
- Published in:
- Journal of Antimicrobial Chemotherapy (JAC), 2023, v. 78, n. 11, p. 2696, doi. 10.1093/jac/dkad285
- By:
- Publication type:
- Article
Limited emergence of resistance to integrase strand transfer inhibitors (INSTIs) in ART-experienced participants failing dolutegravir-based antiretroviral therapy: a cross-sectional analysis of a Northeast Nigerian cohort.
- Published in:
- Journal of Antimicrobial Chemotherapy (JAC), 2023, v. 78, n. 8, p. 2000, doi. 10.1093/jac/dkad195
- By:
- Publication type:
- Article
Maintenance darunavir/ritonavir monotherapy to prevent perinatal HIV transmission, ANRS-MIE 168 MONOGEST study.
- Published in:
- Journal of Antimicrobial Chemotherapy (JAC), 2023, v. 78, n. 7, p. 1711, doi. 10.1093/jac/dkad161
- By:
- Publication type:
- Article
HIV-1 infection in South Kivu (Democratic Republic of Congo): high genotypic resistance to antiretrovirals.
- Published in:
- Journal of Antimicrobial Chemotherapy (JAC), 2023, v. 78, n. 7, p. 1732, doi. 10.1093/jac/dkad163
- By:
- Publication type:
- Article
Four days/week antiretroviral maintenance strategy (ANRS 170 QUATUOR): substudies of reservoirs and ultrasensitive drug resistance.
- Published in:
- Journal of Antimicrobial Chemotherapy (JAC), 2023, v. 78, n. 6, p. 1510, doi. 10.1093/jac/dkad119
- By:
- Publication type:
- Article
Effectiveness and tolerability of dolutegravir/lamivudine for the treatment of HIV-1 infection in clinical practice.
- Published in:
- Journal of Antimicrobial Chemotherapy (JAC), 2023, v. 78, n. 6, p. 1423, doi. 10.1093/jac/dkad102
- By:
- Publication type:
- Article
Increasing trend of transmitted integrase inhibitor resistance in a cohort of antiretroviral therapy-naive people living with HIV.
- Published in:
- Journal of Antimicrobial Chemotherapy (JAC), 2023, v. 78, n. 5, p. 1314, doi. 10.1093/jac/dkad109
- By:
- Publication type:
- Article
Drug resistance in children and adolescents with HIV in Panama.
- Published in:
- Journal of Antimicrobial Chemotherapy (JAC), 2023, v. 78, n. 2, p. 423, doi. 10.1093/jac/dkac407
- By:
- Publication type:
- Article